Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.50 |
| ▸ | JAK2 | O60674 | 3/20 | 0.50 |
| ▸ | JAK1 | P23458 | 3/20 | 0.50 |
| ▸ | TYK2 | P29597 | 2/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588604 | 0.86 | GSK3B (0.47) | JAK2AURKAMARK3MARK4 | |
| SCHEMBL3583884 | 0.86 | GSK3B (0.47) | JAK2AURKAMARK3MARK4 | |
| SCHEMBL3583888 | 0.86 | GSK3B (0.47) | JAK2AURKAMARK3MARK4 | |
| SCHEMBL3587815 | 0.86 | MARK3 (0.42) | AURKACCNA2CDK2CDK4CDK6 | |
| SCHEMBL1355702 | 0.83 | AURKA (0.45) | JAK2AURKAMARK3MARK4EGFR | |
| SCHEMBL1355699 | 0.83 | AURKA (0.45) | JAK2AURKAMARK3MARK4EGFR | |
| SCHEMBL3585284 | 0.82 | AURKA (0.47) | AURKACCNA2CDK2CDK4CCNA1 | |
| SCHEMBL1353831 | 0.81 | MARK3 (0.41) | JAK3JAK2JAK1TYK2FGFR1 | |
| SCHEMBL1355934 | 0.81 | AURKA (0.58) | JAK3JAK2JAK1TYK2FGFR1 | |
| SCHEMBL3585565 | 0.80 | MARK3 (0.42) | FGFR1AURKACCNA2CDK2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | claimed |
| US-20100190787-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190787-A1 | Modulators of Mitotic Kinases | CDK1, BUB1, BUB1B | JAK3 920/4885JAK2 2264/4885JAK1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.